Beta 3 Agonist Treatment in Heart Failure

Trial Profile

Beta 3 Agonist Treatment in Heart Failure

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Dec 2016

At a glance

  • Drugs Mirabegron (Primary)
  • Indications Chronic heart failure
  • Focus Therapeutic Use
  • Acronyms Beat-HF
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 18 Dec 2016 Primary endpoint of increase in LVEF (measured by MRI or CT) has not been met, according to results published in the European Journal of Heart Failure.
    • 18 Dec 2016 Results published in the European Journal of Heart Failure
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top